SCHEMBL1108577

SCHEMBL1108577

COc1ccc(Oc2ccc(S(=O)(=O)N[C@H](C)[C@@]3(C)NC(=O)NC3=O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 11/20 0.44
MMP9 P14780 9/20 0.44
MMP8 P22894 7/20 0.44
MMP13 P45452 7/20 0.44
MMP1 P03956 5/20 0.44
MMP3 P08254 4/20 0.44
MMP7 P09237 3/20 0.44
MMP14 P50281 2/20 0.44
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
PGR P06401 1/20 0.42
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 2/20 0.40
ADAMTS4 O75173 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108587 1.00 MMP2 (0.44) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108557 0.91 FFAR1 (0.42) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108586 0.91 MMP9 (0.51) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108541 0.91 FFAR1 (0.42) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108501 0.91 MMP9 (0.51) MMP2MMP9MMP8MMP13MMP1
SCHEMBL13127434 0.90 SMN1; SMN2 (0.44) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108575 0.89 FFAR1 (0.41) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108545 0.89 PGR (0.41) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108547 0.89 FFAR1 (0.41) MMP2MMP9MMP8MMP13MMP1
SCHEMBL1108564 0.89 PGR (0.41) MMP2MMP9MMP8MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MMP2 9/4885MMP9 1/4885MMP8 14/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MMP2 9/4885MMP9 1/4885MMP8 14/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 MMP2 8/4885MMP9 1/4885MMP8 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.